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ABSTRACT
Question
What is the role of hormonal therapy as adjuvant therapy
in patients with stage I endometrial cancer?
Perspectives
There is little consensus on the role of adjuvant treat-
ment for patients with stage I endometrial cancer. Al-
though the use of hormonal therapy has been established
in advanced disease, less agreement has emerged con-
cerning the benefits of adjuvant hormonal therapy for
patients with early-stage disease. The objective of the
present evidence series was to review the existing lit-
erature on the role of hormonal therapy as adjuvant
therapy in patients with stage I endometrial cancer.
Outcomes
Reports were sought that included at least one of the
following outcomes: overall survival, disease-free sur-
vival, recurrence (local, or distant, or both), adverse
effects, and quality of life. Because of the potential for
long-term adverse effects with adjuvant hormonal treat-
ment in this patient population, especially with regard
to thromboembolic or cardiovascular events, the rates
of non-cancer-related death were also of interest.
Adjuvant hormonal
therapy for stage I
endometrial cancer
L. Gien MD,* J. Kwon MD,† T.K. Oliver BA,‡
M. Fung-Kee-Fung MD,§ and the members
of the Gynecology Cancer Disease Site
Group|| of Cancer Care Ontario’s Program
in Evidence-Based Care
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Methodology
The MEDLINE, EMBASE, and Cochrane Library data-
bases were systematically searched for randomized
controlled trials, practice guidelines, systematic reviews,
and meta-analyses. The resulting evidence informed the
development of the clinical practice guideline. The sys-
tematic review with meta-analyses and practice guide-
line were approved by the Report Approval Panel of the
Program in Evidence-Based Care, and by the
Gynecology Cancer Disease Site Group (DSG).
Results
Nine randomized trials and one published meta-analy-
sis comparing adjuvant hormonal therapy with no
adjuvant therapy in women with stage I endometrial
cancer constituted the evidence base. One trial reported
a statistically significant survival benefit with adjuvant
progestogen as compared with no further treatment
(97% vs. 69%, p < 0.001). In that trial, the treatment
group had a higher number of patients with less myo-
metrial invasion, and a lower number of patients with
advanced-stage disease. These differences in baseline
characteristics between the randomized groups were
considered to be clinically important. In addition, the
results of that trial were not consistent with those of
other trials, and the trial was a source of statistical
heterogeneity when data were pooled across trials.
In two of the nine randomized trials, statistically
significant recurrence-free benefits were detected with
adjuvant hormonal therapy as compared with no further
therapy. In one trial, the difference between the rates of
recurrence was 16%; however, the methodologic con-
cerns related to that that trial limited its relevance. In
the other trial, the difference between the rates of re-
currence was 5%. In that trial, patients were at a high
risk of recurrence. None of the remaining sevenGIEN et al.
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randomized trials reported any significant difference in
recurrence rates between treatment groups.
The meta-analysis identified in the literature de-
tected no statistically significant recurrence-free or
overall survival benefit associated with adjuvant hor-
monal therapy as compared with no adjuvant therapy
[odds ratio (OR): 1.05; 95% confidence interval (CI):
0.88 to 1.24). Those results are consistent with the re-
sults of the meta-analysis in the present report, which
included an additional two trials (OR: 1.10; 95% CI:
0.91 to 1.34).
Practice Guideline
Target Population   This clinical recommendation ap-
plies to women with newly diagnosed stage I endome-
trial cancer.
Recommendation   The available evidence does not
demonstrate any benefit for adjuvant hormonal therapy.
The use of hormonal therapy is not recommended as
adjuvant treatment for patients with stage I endome-
trial cancer.
KEY WORDS
Adjuvant hormonal therapy, stage I endometrial can-
cer, early-stage endometrial cancer
1. QUESTION
What is the role of adjuvant hormonal therapy in pa-
tients with stage I endometrial cancer?
2. CHOICE OF TOPIC AND RATIONALE
Endometrial cancer is the most common gynecologic
cancer in Canada 1. Each year, approximately 3900
women are diagnosed with endometrial cancer in
Canada, about 1550 of whom reside in the province of
Ontario 1. Approximately 75% of patients present with
stage I disease, which is confined to the uterus 2. Pri-
mary surgical treatment for patients with stage I en-
dometrial cancer typically consists either of a total
abdominal hysterectomy with bilateral salpingo-
oophorectomy, or complete surgical staging, which
involves abdominal hysterectomy, bilateral salpingo-
oophorectomy, dissection or sampling of pelvic or
para-aortic nodes (or both), peritoneal cytology, omen-
tectomy, and peritoneal biopsies 3.
There is little consensus on the role of adjuvant
treatment for patients with stage I endometrial cancer.
Currently, there is evidence to support the role of
adjuvant pelvic radiotherapy in stage I endometrial
cancer to reduce risk of recurrence for higher-risk pa-
tients (stage IC, grade 3) and perhaps for patients at
intermediate risk (stage IC, grades 1 or 2; or stage IA
or IB, grade 3), but not for patients at lower risk (stage
IA or IB, grades 1 or 2) 4. Although the use of hormonal
therapy has been established in advanced disease 5,
less agreement has emerged on the role of adjuvant
hormonal therapy in early-stage disease.
The objective of the present evidence series was
to review the existing literature on the role of hormo-
nal therapy as adjuvant therapy in patients with stage I
endometrial cancer.
3. METHODS
3.1 Literature Search Strategy
A literature search was conducted using MEDLINE
(OVID: 1966 through January 2007), EMBASE (OVID:
1988 through January 2007), the Cochrane Library da-
tabase (OVID: Issue 1, 2007), the Physician Data
Query database, the Canadian Medical Association
InfoBase, and the National Guideline Clearinghouse.
In addition, abstracts published in the proceedings of
the meetings of the American Society of Clinical
Oncology (1997–2006) and the European Society for
Medical Oncology (2002–2006) were searched for
evidence relevant to this report. Reference lists of
related papers and recent review articles were also
scanned for additional citations.
The literature search of the electronic databases
combined disease-specific terms (endometrial neo-
plasms/ or endomet:.ti. and cancer.ti. or neoplasms/ or
carcinoma:.ti. or adenocarcinoma:.ti.) with treatment-
specific terms (antineoplastic agents, hormonal/) for
the following study designs: randomized controlled tri-
als (RCTs), practice guidelines, systematic reviews, and
meta-analyses.
3.2 Study Selection Criteria
Articles were selected for inclusion in the systematic
review of the evidence if they randomized patients with
stage I endometrial cancer either to adjuvant hormonal
therapy or to no adjuvant treatment or other forms of
hormonal therapy. To encompass trials in which most
patients had early-stage disease, an a priori decision
was made to include trials if at least 60% of the pa-
tients reported had stage I disease or if results were
reported separately for patients with stage I disease.
The report had to include at least one of the following
outcomes: overall survival, disease-free survival, re-
currence (local, or distant, or both), adverse effects, or
quality of life. Because of the potential for long-term
adverse effects with adjuvant hormonal treatment in
this patient population, especially with regard to throm-
boembolic or cardiovascular events, the rates of non-
cancer-related death were also of interest. It was
determined a priori that the literature search would be
expanded to include other study designs if the initial
search failed to identify sufficient evidence to inform
the systematic review.
Practice guidelines, meta-analyses, or systematic
reviews explicitly based on evidence related to thePRACTICE GUIDELINE SERIES
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guideline question were also eligible for inclusion in
the systematic review.
Articles were excluded from the systematic re-
view of the evidence if they were case reports, letters,
editorials, or papers published in a language other
than English.
3.3 Synthesizing the Evidence
Combining results across trials provides added power
for detecting the efficacy of a treatment and improves
the reliability or confidence of the point estimate. Ide-
ally, data are pooled using hazard ratios (HRs); how-
ever, if that method is not possible given the level of
the data reporting, meta-analyses using point-in-time
estimates are conducted.
For the meta-analysis reported here, data were
analyzed using the Review Manager 4.2.10 statistical
package (The Nordic Cochrane Centre, Copenhagen,
Denmark), obtained through the Cochrane Collabora-
tion (www.cochrane.org). Results are expressed as the
pooled HR or the odds ratio (OR) with 95% confidence
interval (CI), in which a value less than 1.0 favours the
experimental treatment and a value greater than 1.0
favours the control.
As part of combining data in a meta-analysis, an
assessment of heterogeneity is performed. Clinical
heterogeneity is assessed by determining whether the
populations, interventions, and outcomes are suffi-
ciently similar to pool data. Statistical heterogeneity
was assessed by Q test, with a value of p < 0.10 se-
lected as the level at which heterogeneity is deemed to
be present. The I2 statistic quantifies how much het-
erogeneity can be attributed to chance or to a real ef-
fect. If substantial heterogeneity is present, possible
clinical and methodologic reasons are qualitatively
explored. The random effects model is typically cho-
sen over the fixed effects model as the more conserva-
tive estimate of effect.
4. RESULTS
4.1 Literature Search Results
Nine RCTs 6–14 and one published meta-analysis 15 on
adjuvant hormonal therapy for patients with stage I
endometrial cancer met the specified criteria and were
deemed eligible for inclusion in the systematic review
of the evidence. Because the number of RCTs identi-
fied was sufficient, the search was not expanded to
include other study designs.
In the nine trials identified, patients were
randomized to either adjuvant progestogen therapy or
to a control group with no adjuvant therapy 6–14. In
seven trials, patients in the control group received no
further treatment 6–12; in two trials, patients in the con-
trol group received a placebo control. One trial also
included a third group of patients randomized to re-
ceive tamoxifen 6.
4.2 Study Quality
Only two of the nine randomized trials specifically
described the randomization process 6,11; however, an
additional two trials 9,14 were multicentric investiga-
tions that reported centralized randomization proce-
dures. Thus, although randomization and allocation
concealment techniques were not specifically reported,
it can be inferred that adequate randomization occurred
in the latter two trials. Each of the trials reported a
comparison of baseline patient characteristics and im-
portant prognostic variables that could potentially in-
fluence outcome, such as depth of myometrial invasion
and histologic grade. In seven trials 6–7,9–13, baseline
characteristics of the patients in the treatment and con-
trol groups were comparable, demonstrating an ad-
equate randomization process. In the trial by Urbanski
et al. 8, the progestogen group had noticeably more
patients with favourable characteristics in terms of stage
and depth of myometrial invasion, a clinically relevant
difference between groups. Conversely, in the trial by
Lewis et al. 14, the placebo group had more patients
with favourable characteristics with regard to depth of
myometrial invasion.
All of the trials except the trial by Quinn 7 main-
tained their comparison groups. In the Quinn trial, if
recurrence was observed in the control group, the pa-
tients were offered adjuvant hormonal therapy and
crossed over to the treatment group.
Overall survival 6–11,13–14 or recurrence-free sur-
vival 12 were described or inferred as the primary out-
comes of interest upon which power calculations were
based. Only two trials specifically reported their power
calculation 7,11, but omission of that information may
be a reflection of how reporting standards for clinical
trial methodology have changed over time. Five trials
randomized more than 200 patients per arm 7,9–11,14,
two trials 6,8 randomized fewer than 135 patients per
arm, and two trials 12,13 randomized fewer than 30
patients per arm.
An intent-to-treat analysis was reported in five of
the nine trials 7–9,11,13 and not reported in the remain-
ing four trials 6,10,12,14. Intent to treat is a more con-
servative approach to data analysis whereby all patients
are analyzed according to their original randomization
assignment regardless of factors such as drop-out, non-
compliance with treatment, or crossover. Seven stud-
ies had a follow up rate of >80% 6,8,10–14, one study
had a follow-up of 75% 9, and one study did not report
follow-up data 7. Where reported, overall survival was
measured at or beyond the point of median follow-up.
4.3 Trial Characteristics
To be eligible to participate in the trials, patients re-
quired a histologic diagnosis of endometrial adenocarci-
noma and, with the exception of one trial 14, first had to
undergo surgery, which included at least a total abdomi-
nal hysterectomy and bilateral salpingo-oophorectomy,GIEN et al.
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followed by adjuvant radiation therapy if indicated ac-
cording to pathology criteria. In the trial by Lewis et
al. 14, patients were randomized into two groups, one
offering preoperative radiation therapy and surgery, and
one offering surgery alone. (Current practice no longer
uses preoperative radiation therapy.) The progestogen
agents in the adjuvant hormonal therapy groups included
medroxyprogesterone acetate 6,7,9,11,14, hydroxypro-
gesterone caproate 8,10,13, and gestonorone caproate 12.
The doses of hormonal therapy were relatively equiva-
lent in all of the trials, even when compared across
formulations.
In four trials 9,12–14, only patients with stage I dis-
ease (confined to the uterine corpus) were eligible to
participate; in the remaining five trials 6–8,10,11, pa-
tients with more-advanced stages of endometrial can-
cer were also eligible. In the latter trials, at least 60%
of patients were diagnosed with stage I disease 6–8,10,11.
The trial reported by Quinn had specific inclusion cri-
teria for patients with histologically high-risk endome-
trial cancer in addition to stage I disease 7.
Furthermore, that trial performed a subgroup analy-
sis of the patients after removing 117 women consid-
ered ineligible after pathology review. In three other
trials, subgroup analyses of high-risk endometrial can-
cer were performed 6,10,12. In those three trials, the
subgroup analyses were not decided a priori, and they
were therefore likely not to have adequate power for
significant results. In the present review, data on sub-
group analyses are not reported.
Protocols for changes in treatment were specified
in three of the nine randomized trials, with patients
who experienced a recurrence in the control group be-
ing able to cross over to the hormonal treatment group 7
or with patients who experienced side effects having
the option to stop treatment 9,11. In the trials in which
patients had the option to stop treatment because of
side effects, patients who stopped treatment were still
analyzed according to the intent-to-treat approach 9,11.
The trials were conducted in Germany 6, Australia 7,
Poland 8, Italy 9,12, Norway 10, the United Kingdom 11,
and the United States 13,14.
4.4 Outcomes
Does hormonal therapy used as adjuvant treatment for
early-stage endometrial cancer improve recurrence and
survival outcomes for patients, and is overall quality
of life affected? Is hormonal therapy more likely to be
useful for well-differentiated tumours than for poorly-
differentiated tumours?
The sections that follow outline key findings re-
garding recurrence rates, survival, and adverse events,
including non-cancer-related deaths.
No identified trial answered the questions regard-
ing quality of life or tumour differentiation, nor did they
report compliance with treatment. It should also be
noted that reporting conventions have changed over
time, and because the identified trials span a 30-year
period, some data considered standard by today’s con-
ventions are missing in the reporting of the trials (for
example, reporting of HRs, common-point-in-time es-
timates, adverse events, compliance with treatment,
and so on). Data from the trials were extracted as avail-
able. Table I summarizes the recurrence and survival
results of the nine trials.
4.4.1 Survival
Of the nine randomized trials, one trial detected a sta-
tistically significant difference in overall survival be-
tween the treatment group, who received
hydroxyprogesterone caproate, and the control group,
who received no further treatment 8. In that trial (by
Urbanski et al.), the overall survival rate at 5 years
was 97% in the treatment group as compared with 69%
in the control group. Although 70% of the patients had
stage I disease, the foregoing results were based on all
205 patients with stages I–III endometrial cancer. A criti-
cism of the trial is that the prognostic variables in the
two groups were not equally distributed at baseline: the
treatment group had a higher number of patients with
less myometrial invasion, and a lower number of pa-
tients with advanced-stage disease. These differences
in baseline characteristics between the randomized
groups were considered to be clinically important.
The remaining eight trials did not find any statisti-
cally significant differences between the treatment and
control groups 6,7,9–14. The overall survival results from
the trial reported by Quinn 7 may have been tempered
by the crossover of 64 of the 107 control patients to
hormonal therapy at recurrence; however, outside of
subgroup analyses, the effect of crossover on survival
is unknown.
The data were sufficient to pool the total number
of deaths in the treatment and the control groups across
all trials 6–14; however, because the data reporting was
variable, it was not possible to conduct meta-analyses
using HRs, and identical points in time could not be
captured. The total numbers of deaths were pooled
across different time points as an alternative method
of pooling data. In one trial in which data were not
directly reported, data were estimated from informa-
tion reported in the trial using the intent-to-treat popu-
lation as the denominator 12.
As seen in Figure 1, meta-analysis demonstrated
no statistically significant difference in overall survival
between patients who received an adjuvant hormonal
therapy and patients in the control groups (OR: 0.96;
95% CI: 0.67 to 1.37). The data were statistically het-
erogeneous (p = 0.0004, I2 = 72.1%), and sensitivity
analysis determined that the source of the statistical
heterogeneity was the trial by Urbanski et al. 8. Given
that the Urbanski et al. trial was the source of the sta-
tistical heterogeneity and that the unequal distribution
of prognostic variables at baseline in that trial was clini-
cally relevant, that trial was removed from the pooled
analysis. As seen in Figure 2, when the Urbanski et al. 8PRACTICE GUIDELINE SERIES
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trial was removed, the heterogeneity of the meta-
analysis was no longer statistically significant (p =
0.27, I 2 = 20.6%), and the difference in overall sur-
vival remained nonsignificant between groups (OR:
1.10; 95% CI: 0.91 to 1.34).
4.4.2 Recurrence
Recurrence rates were reported in six of the nine
randomized trials 6–10,12. Of those six trials, two re-
ported a statistically significant difference in recurrence
rates between treatment groups 7,8. In the trial by Quinn 7,
in which all patients were at a high risk of recurrence,
21% of the control group as compared with 16% of the
hormonal treatment group experienced a relapse (p <
0.05). In the trial by Urbanski et al. 8, 23% of patients
in the control group as compared with 7% of the pa-
tients in the hormonal therapy group recurred (p < 0.001).
The remaining four trials showed no statistically sig-
nificant difference in recurrence rates between the
treatment and control groups 6,9,10,12.
Six of the nine trials provided sufficient informa-
tion to pool the total number of recurrences in both the
treatment and control groups using point-in-time
estimates 6–10,12. The reporting of data was again variable
across the randomized trials, and thus the total num-
bers of recurrences were pooled across various time
points. Data were estimated from information reported
in one trial using the intent-to-treat population as the
denominator 12.
As seen in Figure 3, although fewer recurrences
were associated with adjuvant progestogens, no statis-
tically significant differences in recurrence rate were
detected between patient groups (OR: 0.74; 95% CI: 0.51
to 1.08) and statistically significant heterogeneity was
detected (p = 0.04, I2 = 57.2%). The source of the sta-
tistical heterogeneity was once again deemed to origi-
nate in the trial by Urbanski et al. 8. As seen in Figure
4, when that trial was removed from the pooled analy-
sis, the remaining five trials 6,7,9,10,12 were statisti-
cally homogeneous (p = 0.26, I2 = 24.5%), and the
difference in recurrence remained nonsignificant be-
tween groups (OR: 0.85; 95% CI: 0.65 to 1.10).
4.5 Adverse Events
Table II summarizes the adverse effects reported across
the nine randomized trials 6–14. Five trials reported data
FIGURE 1   Meta-analysis of deaths with adjuvant hormonal therapy versus control (9 trials). OR = odds ratio; CI = confidence interval.
FIGURE 2   Meta-analysis of deaths with adjuvant hormonal therapy versus control (8 trials). OR = odds ratio; CI = confidence interval.PRACTICE GUIDELINE SERIES
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on major harmful side effects or deaths unrelated to
the malignancy, and three trials reported on minor
symptomatic side effects or withdrawals because of
toxicity 6,9,11. The most common minor side effects
included weight gain, peripheral edema, and nausea 6,9.
One trial reported an incidence of overall minor side
effects of 53% in the progestin group and 16% in the
control group, but did not indicate whether the differ-
ence was statistically significant 6. Another trial reported
a minor side effect rate of 12%, but did not calculate
side effects for patients in the control group 9. Macdonald
et al. reported that 4% of patients in the hormonal therapy
group developed hypertension, which disappeared after
the drug was stopped 11. The drop-out rate attributable
to toxicity ranged from 5% to 19% in the three trials that
reported data on that outcome 6,9,11.
Serious side effects included thromboembolic events
such as deep vein thrombosis, pulmonary embolus, and
stroke, or cardiovascular disease such as myocardial
infarction and deterioration of congestive heart fail-
ure. In the trials that reported these events, there were
no statistically significant differences reported be-
tween the treatment and control groups 6,7,9–11. One
trial 6 indicated a serious side effect rate of 6% in the
progestogen group as compared with 2% in the con-
trol group (p value not reported), and another trial 10
reported higher rates of death from cardiovascular
disease in the first 2 years in the progestogen group
than in the control group (5% vs. 3%, p = 0.07). Addition-
ally, deaths that were not attributable to malignancy were
related mainly to cardiovascular or thromboembolic
causes. Only one trial10 showed a statistically signifi-
cant difference in deaths unrelated to malignancy (9%
of patients in the hormonal group vs. 6% of patients in
the control group, p = 0.04). In the trial by Urbanski et
al. 8, the only trial to report an overall survival differ-
ence, 11 patient deaths unrelated to malignancy occurred
in the control arm, and none occurred in the treatment
arm (p value not reported). The remaining trials that
reported deaths unrelated to malignancy did not de-
tect any statistically significant difference between
the treatment and control groups 6,7,9,11.
4.6 Quality of Life
None of the studies reported data on quality of life.
4.7 Meta-Analysis Identified by the Literature
Search
Martin–Hirsch et al. 15 conducted a meta-analysis of
published data comparing adjuvant progestin therapy to
no adjuvant therapy in endometrial cancer. The authors
identified seven 7–11,13,14 of the nine trials 6–14 included
in the present systematic review of the evidence. These
authors also excluded the trial by Urbanski et al. 8 on
the basis of clinical and statistical heterogeneity, and
reported no significant difference in overall survival
between patients who received progestin therapy and
FIGURE 3   Meta-analysis of recurrences with adjuvant hormonal therapy versus control (6 trials). OR = odds ratio; CI = confidence interval.
FIGURE 4    Meta-analysis of recurrences with adjuvant hormonal therapy versus control (5 trials). OR = odds ratio; CI = confidence interval.GIEN et al.
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those who received no adjuvant treatment (OR: 1.05;
95% CI: 0.88 to 1.24; p = 0.6). They also identified three
trials that reported recurrence rates 7,9,10. Again, with
the removal of the trial by Urbanski et al. 8, a marginal
reduction in recurrence rate was detected among women
receiving progestin therapy as compared with women
receiving no adjuvant therapy (OR: 0.81; 95% CI: 0.65 to
1.01; p = 0.06); however, the rate was not statistically
significant. Meanwhile, the authors reported that the rate
of non-cancer-related deaths was significantly higher in
the progestin group (OR: 1.33; 95% CI: 1.02 to 1.73),
presumably because of the adverse cardiovascular ef-
fects of progestin treatment.
The meta-analysis in the present review of the
evidence included two additional trials, the trials by
von Minckwitz 6 and De Palo 12. Overall, aside from
the additional trials, the results of the two meta-analy-
ses were highly comparable.
5. CONCLUSIONS
Nine randomized trials and one meta-analysis of pub-
lished data provide the evidence base for assessing the
role of adjuvant hormonal therapy in women with stage
I endometrial cancer. Several factors limit the inter-
pretability of the results, but the greatest limiting fac-
tor is that the trials, which span a 30-year period,
generally have inconsistent reporting throughout. The
inconsistencies limit the quality assessment of inter-
nal validity related to patient and study characteristics
and to outcomes. No quality-of-life data, little data on
adverse events or treatment compliance, and limited
data on recurrence and survival outcomes, especially in
regard to HRs and time-to-event estimates, were re-
ported. There were also differences in patient populations,
unexpected findings that were not consistent with the
results of similar randomized trials, and notable discrep-
ancies between patients at baseline despite the
randomization process. These limitations affected the
external validity of the trials; however, these trials pro-
vide the only randomized data that inform the role of
adjuvant hormonal therapy in this patient population.
Despite the limitations, the evidence was consist-
ent in the direction of effect: adjuvant hormonal therapy
does not confer a survival advantage in patients with
stage I endometrial cancer. Eight of the nine randomized
trials failed to detect any difference in survival between
the treatment group and the control group. The remain-
ing trial did demonstrate a survival difference, but the
quality of that trial is subject to criticism because of
important differences in baseline characteristics be-
tween the patient groups. Moreover, the trial results
were not consistent with the results of the other identi-
fied RCTs. The magnitude of the effect is highly unex-
pected when reviewed in comparison with the results
of the other similar trials reported. Also, in two meta-
analyses, no survival advantages were detected with
adjuvant hormonal therapy.
In seven of the nine randomized trials, recurrence
rates were not significantly different between patients
TABLE II    Adverse events of adjuvant hormonal therapy in early endometrial cancer
Study Patients Treatment                  Adverse events Withdrawal Second Deaths
(n) groups Minor Serious because of primary not related
(%) (%) toxicity malignancy to cancer
(%) (%) (%)
von Minckwitz et al., 2002 6 134 None 16 2 — 6 9
133 Progestogen 53 6 19 7 10
121 Tamoxifen 34 3 3 2 6
Quinn, 1998 7 507 None NR 4—< 11 3
505 Progestogen NR 5 NR 21 5
Urbanski et al., 1993 8 105 None NR NR — NR 10
100 Progestogen NR NR NR NR 0
De Palo et al., 1993 9 370 None NR 3— 3 5
348 Progestogen 12 2 5 1 4
Vergote et al., 1989 10 531 None NR 3—< 1 6
553 Progestogen NR 5 NR 19
(p=0.04)
Macdonald et al., 1988 11 215 None NR 4—NR 11
214 Progestogen 4 a 31 1NR 10
De Palo et al., 1983 12 30 None NR NR —3NR
32 Progestogen NR NR NR 3 NR
Malkasian and Bures 1978 13 17 Placebo NR NR NR NR 6
18 Progestogen NR NR NR NR 11
Lewis et al., 1974 14 287 Placebo NR NR NR NR NR
285 Progestogen NR NR NR NR NR
a   The only minor adverse event reported was hypertension.
No p values were reported, except where indicated. NR = not reported.PRACTICE GUIDELINE SERIES
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in the adjuvant hormonal groups and patients in the
control groups. Of the two trials that detected lower
recurrence rates in patients in the progestin group, the
trial by Urbanski et al. 9 reported more favourable base-
line characteristics for patients in the treatment group,
and the trial by Quinn 7 reported data on patients at
high risk of recurrence. Although the meta-analysis in
the present review and the previously published meta-
analysis showed a marginal reduction in recurrence
rate with adjuvant therapy, that reduction was not sta-
tistically significant at the 0.05 level.
Finally, although not consistently reported, the
rates of adverse events among patients in the hor-
monal groups were generally higher than those
among patients in the control groups. Minor side ef-
fects were reported more often in the treatment
groups, although tests of statistical significance were
not performed. The rate of non-cancer-related death
was shown to be higher with progestogen in one
randomized trial, mainly because of cardiovascular
or thromboembolic events (p = 0.04). In contrast,
Urbanski et al. 8 reported a 10% non-cancer-related
death rate in the control group and a 0% rate in the
treatment group. This unexpected finding not seen in
the other randomized trials. The meta-analysis by
Martin–Hirsch et al. 15 did not demonstrate a statis-
tically significant difference in non-cancer-related
death.
Unfortunately, the data reported in the randomized
trials were insufficient to stratify patients with stage I
disease by high as compared with low risk of recur-
rence. Whether the subgroups of patients who were at
a higher risk of recurrence (stage IC, grade 3) would or
would not have benefited from adjuvant hormonal
therapy cannot be fully answered by the available data.
Interpretation is further confounded by the fact that five
of the nine randomized trials included between 10%
and 35% of patients with greater than stage I disease.
Further investigation by risk of recurrence should be
the focus of future research.
Given the lack of an overall survival benefit, the
marginal decrease in recurrence rate (seen mainly in
patients at higher risk of recurrence), and the need for
treatment regimens that can span years with possible
increases in adverse events, the evidence is currently
insufficient to support the use of hormonal therapy as
adjuvant treatment for patients with early-stage en-
dometrial cancer.
6. FUTURE RESEARCH
The randomized trials completed to date have stud-
ied the use of specific types of progestogens in early
endometrial cancers, and one trial included tamoxifen
as a comparison group 6. Future trials can potentially
include other anti-estrogenics, selective estrogen
receptor modulators, aromatase inhibitors, and
estrogen receptor downregulators in homogenous pa-
tient populations.
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